Content provided in partnership with

Business Services Industry

Oculus Innovative Sciences Announces Initial Chinese Commercialization Plan for Launch of Microcyn® Technology

Business Wire, May 5, 2008

Oculus Team Meets in Beijing with Chinese Distributor to Review Product Labeling, Collateral Design, Sales Training Materials and Reimbursement Strategy

PETALUMA, Calif. -- Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn[R] Technology platform that is intended to treat infections in chronic and acute wounds, announced today that the Oculus development team completed meetings this past week in Beijing, China with Chinese partners at China Bao Tai and Sinopharm regarding commercialization plans for the product launch of Microcyn Technology in China.

Most Popular Articles in Business: Research and Markets : Tesco Plc - SWOT Framework Analysis; Do Us a Flavor - Ben & Jerry's Issues a Call for Euphoric New Flavors; eBay made easy: ready to start an eBay business? These 5 simple steps will ...; Katrina's lawsuit surge: a legal battle to force insurers to pay for flood ...; Wal-Mart's newest distribution center opened last month near the southwest ...; More »

Oculus Innovative Sciences entered into an agreement with China Bao Tai in 2007 for the distribution of Microcyn-based products in China. The partnership allows Oculus and the Microcyn Technology to gain a foothold in China through China Bao Tai and its various sub-distributors, including Sinopharm and Lianhua Supermarket Holdings Co., Ltd.

The first phase of the Chinese commercialization plan includes sampling of Chinese wound care professionals with the Microcyn-based Dermacyn[TM] product. This will initially target key opinion leaders via trials at multiple medical centers for the purpose of securing both post-market clinical data and reimbursement. Dermacyn was approved in March of this year by the Chinese State Food and Drug Agency (SFDA) as a technology that provides a moist environment for wounds and accelerates wound healing through the reduction of microorganisms in wounds.

In results from Oculus' recently completed U.S. Phase II clinical trial evaluating Microcyn[R] Technology as a topical antimicrobial treatment for mildly infected diabetic foot ulcers, the clinical success rate at the test-of-cure visit for Microcyn-alone-treated evaluable patients was 93% compared to 56% for the levofloxacin (antibiotic) plus saline-treated patients. This data, along with complementary results from more than 25 other additional Microcyn trials previously completed, is a key message for the Chinese market since it indicates that Microcyn use can reduce the need for systemic antibiotics, the overuse of which is responsible for the global epidemic of antibiotic-resistant bacteria and viruses such as MRSA.

Hoji Alimi, CEO and founder of Oculus said, "It is vital that the Microcyn Technology be properly positioned and its wide spectrum of potential applications fully communicated to the Chinese medical community. To that end, the Oculus team and our Chinese partners are crafting a launch plan that is designed for short- and long-term success, further underscoring our commitment to this important market. We believe this well-conceived, multi-tiered commercialization strategy will provide patients with the latest advance in both anti-infective and wound healing technologies and Oculus shareholders with the optimum return in this enormous market of 1.3 billion people."

Chinese Healthcare Market

According to Journal of the American Medical Association, as is the case in much of the rest of the world, the aged proportion of China's population is increasing. The population older than 65 years included 100.4 million persons, or 7.69% of China's total population, in 2005 and is expected to increase at an annual rate of 3.28%. With this increased aged population, total health care needs and expenditures will increase as well. China's proportion of GDP allocated to health care, currently about 5.55%, is likely to increase steadily to become closer to that of developed countries, most of which have comparable rates of 8% to 11%, up to nearly 16% in the United States.

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the prevalence of type 2 diabetes in China is staggering, rivaling that of the United States, Europe, and Japan combined. According to a new Emerging Markets-China report entitled Type 2 Diabetes in China, the type 2 diabetes drug market in China will reach $1.3 billion in 2010. The report also finds that increasing economic power in China has led to growing numbers of patients with supplementary healthcare insurance and an improved ability to afford Western-branded drugs.

About China Bao Tai Investment Company

China Bao Tai Investment Co., Ltd. is a diversified investment company with a focus on health care, high-tech, new energy sources, and environmental protection. It is registered with the State Administration for Industry and Commerce of the People's Republic of China. China Bao Tai has extensive experience introducing new products and technologies into China and enjoys a productive working relationship with both local and central government agencies. They will utilize various sub-distributors for hospitals, independent pharmacies and retail pharmacies. In that effort, China Bao Tai has reached agreement with two key sub-distributors:

Sinopharm for hospital and pharmacy distribution

Business Services Industry

Oculus Innovative Sciences Announces Initial Chinese Commercialization Plan for Launch of Microcyn® Technology

Business Wire, May 5, 2008

Find Research Guides for:

Find Featured Titles for: Reference

Most Popular Articles in Business

Most Popular Publications in Business